D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 92 Citations 36,012 400 World Ranking 5414 National Ranking 3029

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Disease
  • Cancer

His primary areas of investigation include Internal medicine, Immunology, Lupus erythematosus, Rheumatology and Placebo. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Surgery. His work carried out in the field of Immunology brings together such families of science as Tolerability and Disease.

The various areas that Daniel J. Wallace examines in his Lupus erythematosus study include Anti-nuclear antibody, Systemic lupus erythematosus, Lupus nephritis and Chemotherapy. His research integrates issues of Systemic disease, Physical therapy, Biomarker and Clinical significance in his study of Rheumatology. His studies deal with areas such as Tabalumab, Belimumab, Adverse effect and Randomized controlled trial as well as Placebo.

His most cited work include:

  • Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. (2280 citations)
  • The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes (1362 citations)
  • A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus (932 citations)

What are the main themes of his work throughout his whole career to date?

Daniel J. Wallace mainly focuses on Internal medicine, Immunology, Lupus erythematosus, Systemic lupus erythematosus and Rheumatology. The Internal medicine study combines topics in areas such as Gastroenterology and Placebo. In his study, Cyclophosphamide is strongly linked to Lupus nephritis, which falls under the umbrella field of Immunology.

His Lupus erythematosus study combines topics in areas such as Surgery, MEDLINE, Belimumab, Disease and Severity of illness. His Systemic lupus erythematosus research is multidisciplinary, relying on both Dermatology and Intensive care medicine. His Rheumatology research incorporates themes from Anti-nuclear antibody and Physical therapy.

He most often published in these fields:

  • Internal medicine (52.45%)
  • Immunology (33.06%)
  • Lupus erythematosus (29.80%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (52.45%)
  • Lupus erythematosus (29.80%)
  • Systemic lupus erythematosus (26.12%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Internal medicine, Lupus erythematosus, Systemic lupus erythematosus, Rheumatology and Immunology. His Internal medicine research integrates issues from Gastroenterology, Placebo and Anti-nuclear antibody. His work deals with themes such as Monoclonal, Young adult, Dermatology, Disease and Severity of illness, which intersect with Lupus erythematosus.

The study incorporates disciplines such as Medical record, Prospective cohort study, Quality of life and Hazard ratio in addition to Systemic lupus erythematosus. His Rheumatology study combines topics in areas such as Cohort study, MEDLINE, Autoantibody, Rheumatism and Frailty Index. Within one scientific family, Daniel J. Wallace focuses on topics pertaining to Gene expression under Immunology, and may sometimes address concerns connected to Interferon and Janus kinase.

Between 2017 and 2021, his most popular works were:

  • 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus (197 citations)
  • 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus (173 citations)
  • Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial (171 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Disease
  • Cancer

His main research concerns Internal medicine, Lupus erythematosus, Systemic lupus erythematosus, Rheumatology and Young adult. His studies link Anti-nuclear antibody with Internal medicine. His Lupus erythematosus research includes themes of Predictive value of tests, Randomized controlled trial, Severity of illness and Monoclonal.

He has researched Systemic lupus erythematosus in several fields, including Quantitative trait locus, Prospective cohort study and Medical record. The various areas that Daniel J. Wallace examines in his Rheumatology study include Autoantibody, Frailty Index and Hazard ratio. The study incorporates disciplines such as Autoimmune disease, Disease, Incidence and Nephritis in addition to Young adult.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

Michelle Petri;Ana Maria Orbai;Graciela S. Alarcõn;Caroline Gordon.
Arthritis & Rheumatism (2012)

3514 Citations

Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial

Joan T. Merrill;C. Michael Neuwelt;Daniel J. Wallace;Joseph C. Shanahan.
Arthritis & Rheumatism (2010)

1359 Citations

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

Bevra H. Hahn;Maureen A. McMahon;Alan Wilkinson;W. Dean Wallace.
Arthritis Care and Research (2012)

1287 Citations

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes

Matthew H. Liang;Michael Corzillius;Sang Cheol Bae;Robert A. Lew.
Arthritis & Rheumatism (1999)

1243 Citations

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Richard Furie;Michelle Petri;Omid Zamani;Ricard Cervera.
Arthritis & Rheumatism (2011)

1212 Citations

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

Ellen M. Ginzler;Mary Anne Dooley;Cynthia Aranow;Mimi Y. Kim.
The New England Journal of Medicine (2005)

1204 Citations

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).

Christian E. Antoni;Arthur Kavanaugh;Bruce Kirkham;Zuhre Tutuncu.
Arthritis & Rheumatism (2005)

810 Citations

Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis.

M Linker-Israeli;R J Deans;D J Wallace;J Prehn.
Journal of Immunology (1991)

655 Citations

Dubois' Lupus Erythematosus

Daniel J. Wallace.
(1987)

653 Citations

A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.

Dimitrios T. Boumpas;Richard Furie;Susan Manzi;Gabor G. Illei.
Arthritis & Rheumatism (2003)

619 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Daniel J. Wallace

Michelle Petri

Michelle Petri

Johns Hopkins University School of Medicine

Publications: 166

John B. Harley

John B. Harley

Cincinnati Children's Hospital Medical Center

Publications: 157

David A. Isenberg

David A. Isenberg

University College London

Publications: 144

Yehuda Shoenfeld

Yehuda Shoenfeld

Sheba Medical Center

Publications: 132

Judith A. James

Judith A. James

Oklahoma Medical Research Foundation

Publications: 114

Graciela S. Alarcón

Graciela S. Alarcón

University of Alabama at Birmingham

Publications: 104

Dafna D. Gladman

Dafna D. Gladman

Toronto Western Hospital

Publications: 102

Caroline Gordon

Caroline Gordon

University of Birmingham

Publications: 95

Ricard Cervera

Ricard Cervera

University of Barcelona

Publications: 95

Andrea Doria

Andrea Doria

University of Padua

Publications: 94

George C. Tsokos

George C. Tsokos

Beth Israel Deaconess Medical Center

Publications: 91

Ian N. Bruce

Ian N. Bruce

University of Manchester

Publications: 87

Murray B. Urowitz

Murray B. Urowitz

Toronto Western Hospital

Publications: 83

Rosalind Ramsey-Goldman

Rosalind Ramsey-Goldman

Northwestern University

Publications: 82

Dimitrios T. Boumpas

Dimitrios T. Boumpas

National and Kapodistrian University of Athens

Publications: 79

Joan T. Merrill

Joan T. Merrill

Oklahoma Medical Research Foundation

Publications: 74

Something went wrong. Please try again later.